title: GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controlled trial.
abstract: OBJECTIVE
  To assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.
  
  
  METHODS
  Single-center, randomized, single-blind, placebo-controlled trial.
  
  
  METHODS
  University-affiliated infertility clinic, between February 2005 and December 2007.
  
  
  METHODS
  Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication.
  
  
  METHODS
  Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n=172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time.
  
  
  METHODS
  Pregnancy rate was the primary outcome measure considered for assessing the role of triptorelin administration at the time of implantation. Clinical pregnancy, miscarriage, and ongoing pregnancy rates were the secondary outcome measures.
  
  
  RESULTS
  No differences were detected between the groups regarding clinical, seminal, or ovarian stimulation parameters. Pregnancy rate per randomized patient was similar in both groups (22.7% vs. 22.1%), as were clinical pregnancy, miscarriage, and ongoing pregnancy rates. There was a significant increase in the proportion of multiple pregnancies in the placebo group (10.3% vs. 36.8%).
  
  
  CONCLUSIONS
  Administration of GnRH agonist at the time of implantation does not improve the reproductive outcome of IUI cycles.
authors.affiliation: Department of Reproduction, Instituto Valenciano de Infertilidad, University of Valencia, Valencia, Spain. jbellver@ivi.es
authors.forename: José
authors.initials: J
authors.lastname: Bellver
authors.forename: Elena
authors.initials: E
authors.lastname: Labarta
authors.forename: Ernesto
authors.initials: E
authors.lastname: Bosch
authors.forename: Marco A B
authors.initials: MA
authors.lastname: Melo
authors.forename: Carmina
authors.initials: C
authors.lastname: Vidal
authors.forename: José
authors.initials: J
authors.lastname: Remohí
authors.forename: Antonio
authors.initials: A
authors.lastname: Pellicer
mesh_terms: D000328:Adult; D000465:Algorithms; D004334:Drug Administration Schedule; D010064:Embryo Implantation / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007315:Insemination, Artificial / Q000379:methods*; D008297:Male; D010919:Placebos; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D016037:Single-Blind Method; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000008:administration & dosage*; D014599:Uterus
chemical_list: D005300:Fertility Agents, Female; D010919:Placebos; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone